Adaptive recurrence risk predictions to optimise prostate cancer follow-up: Results of model validation and clinical impact - report from EAU 2026

Joran Schoorlemmer presents the results of model validation and the clinical impact of adaptive recurrence risk predictions, focusing on how these tools can optimise follow-up strategies for prostate cancer at the EAU 2026 Annual Congress.Video: https://medicaldigest.org/scientific-contents/interview:adaptive-recurrence-risk-predictions-optimise-prostate-cancer-follow-results-model-validation-and-clinical-impact